Trial Outcomes & Findings for A Phase I/II Trial of Stereotactic Body Radiation Therapy (NCT NCT00591838)

Last Updated: 2019-07-30

Results Overview

The phase 1 portion had a "5+3" strategy with four escalating dose levels, only one of which was open for accrual at any time. Five patients were accrued to each dose level, and once closed, the next dose level could not be opened until the preceding dose was deemed acceptable. With a minimum of 90 days from the start of RT, if there were no acute grade 3 or 4 non-hematologic toxicities in the five patients, the current dose was deemed acceptable. If one such toxicity was observed, an additional 3 patients were recruited and followed for a minimum of 90 days. If 2 or more such toxicities were observed, the current dose was determined as dose limiting, and the previous dose level was used for the phase 2 portion.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

74 participants

Primary outcome timeframe

Completion of phase I enrollment (Phase I enrollment took 4 years)

Results posted on

2019-07-30

Participant Flow

The study opened to participant enrollment on 09/21/2006 and closed to participant enrollment on 11/01/2017.

5 participants in the Phase II portion of study were treated errantly with 10 Gy fractions, rather than 11 Gy fractions, but were included in the analysis as intention-to-treat.

Participant milestones

Participant milestones
Measure	Phase I Dose Level A: SBRT 9Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level B: SBRT 10Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase II: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
Overall Study STARTED	5	6	6	6	51
Overall Study COMPLETED	5	6	6	5	51
Overall Study NOT COMPLETED	0	0	0	1	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Phase I Dose Level A: SBRT 9Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level B: SBRT 10Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase II: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
Overall Study Withdrawal by Subject	0	0	0	1	0

Baseline Characteristics

A Phase I/II Trial of Stereotactic Body Radiation Therapy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase I Dose Level A: SBRT 9Gy x 5 Fractions n=5 Participants -Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level B: SBRT 10Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase II: SBRT 11Gy x 5 Fractions n=51 Participants -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.	Total n=74 Participants Total of all reporting groups
Age, Continuous	71 years n=5 Participants	79.5 years n=7 Participants	78 years n=5 Participants	73.5 years n=4 Participants	73 years n=21 Participants	74.5 years n=8 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	4 Participants n=4 Participants	23 Participants n=21 Participants	29 Participants n=8 Participants
Sex: Female, Male Male	4 Participants n=5 Participants	6 Participants n=7 Participants	5 Participants n=5 Participants	2 Participants n=4 Participants	28 Participants n=21 Participants	45 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	0 Participants n=5 Participants	2 Participants n=7 Participants	5 Participants n=5 Participants	6 Participants n=4 Participants	50 Participants n=21 Participants	63 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	4 Participants n=5 Participants	4 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	10 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Black or African American	4 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	0 Participants n=4 Participants	8 Participants n=21 Participants	16 Participants n=8 Participants
Race (NIH/OMB) White	1 Participants n=5 Participants	4 Participants n=7 Participants	0 Participants n=5 Participants	5 Participants n=4 Participants	39 Participants n=21 Participants	49 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants	6 Participants n=8 Participants
Region of Enrollment United States	5 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	51 Participants n=21 Participants	74 Participants n=8 Participants

PRIMARY outcome

Timeframe: Completion of phase I enrollment (Phase I enrollment took 4 years)

Population: Phase I participants were the only participants evaluable for this outcome measure

Outcome measures

Outcome measures
Measure	Phase I: Stereotactic Body Radiation (SBRT) n=22 Participants SBRT Dose Level A 9Gy x 5 fractions Dose Level B 10 Gy x 5 fractions Dose Level C 11 Gy x 5 fractions Dose Level D 12 Gy x 5 fractions	Phase I Dose Level B: SBRT 10Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
Phase I Portion Only: Determine the Maximum Tolerated Dose of SBRT	11 Gy x 5 fractions	—	—	—

PRIMARY outcome

Timeframe: Up to 90 days

Population: -Phase I participants were the only evaluable participants for this outcome measure.

* CTCAE version 3.0 will be used to grade toxicity * Acute toxicity are adverse events that occur from start of treatment through 90 days

Outcome measures

Outcome measures
Measure	Phase I: Stereotactic Body Radiation (SBRT) n=5 Participants SBRT Dose Level A 9Gy x 5 fractions Dose Level B 10 Gy x 5 fractions Dose Level C 11 Gy x 5 fractions Dose Level D 12 Gy x 5 fractions	Phase I Dose Level B: SBRT 10Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity Lymphopenia	0 Participants	1 Participants	0 Participants	0 Participants
Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity Neutrophils/granulocytes (ANC/AGC)	0 Participants	1 Participants	0 Participants	0 Participants
Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity Arthritis (non-septic)	0 Participants	1 Participants	0 Participants	0 Participants
Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity Flu-like syndrome	0 Participants	0 Participants	0 Participants	1 Participants
Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity Glucose, serum-high (hyperglycemia)	0 Participants	1 Participants	0 Participants	0 Participants
Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity Sodium, serum-low (hyponatremia)	0 Participants	1 Participants	0 Participants	0 Participants
Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity Cataract	1 Participants	0 Participants	0 Participants	0 Participants
Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity Dyspnea (shortness of breath)	0 Participants	1 Participants	0 Participants	1 Participants

PRIMARY outcome

Timeframe: 91 days to 2 years

Population: -Phase I participants were the only participants evaluable for this outcome measure

* CTCAE version 3.0 will be used to grade toxicity * Late toxicity are adverse events that occur from Day 91 through 2 years

Outcome measures

Outcome measures
Measure	Phase I: Stereotactic Body Radiation (SBRT) n=5 Participants SBRT Dose Level A 9Gy x 5 fractions Dose Level B 10 Gy x 5 fractions Dose Level C 11 Gy x 5 fractions Dose Level D 12 Gy x 5 fractions	Phase I Dose Level B: SBRT 10Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions n=6 Participants -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Atrial fibrillation	0 Participants	0 Participants	1 Participants	0 Participants
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Pneumonia	0 Participants	2 Participants	2 Participants	2 Participants
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Hypoxia	0 Participants	0 Participants	1 Participants	0 Participants
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Cough	0 Participants	0 Participants	1 Participants	0 Participants
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Prolonged QTc interval	0 Participants	0 Participants	1 Participants	0 Participants
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Generalized weakness	0 Participants	0 Participants	0 Participants	0 Participants
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Chest/thorax NOS pain	0 Participants	0 Participants	1 Participants	0 Participants
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Dyspnea	1 Participants	3 Participants	4 Participants	2 Participants
Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity Pneumonitis/pulmonary infiltrates	0 Participants	0 Participants	1 Participants	1 Participants

PRIMARY outcome

Timeframe: 2 years

Population: Phase I participants were not evaluable for this outcome measure. 1 patient in Phase II did not come back for follow-up. The remaining 50 participants were analyzed for the outcome measure but only those who were not lost to follow-up or deceased at 2 years were included in the outcome measure results.

Local control rate is defined as the absence of isolated failure (progression) within the primary tumor and involved lobe

Outcome measures

Outcome measures
Measure	Phase I: Stereotactic Body Radiation (SBRT) n=50 Participants SBRT Dose Level A 9Gy x 5 fractions Dose Level B 10 Gy x 5 fractions Dose Level C 11 Gy x 5 fractions Dose Level D 12 Gy x 5 fractions	Phase I Dose Level B: SBRT 10Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
Phase II Portion Only: Local Control Rate	85 percentage of participants Interval 62.0 to 95.0	—	—	—

SECONDARY outcome

Timeframe: 2 years

Regional nodal recurrence is defined as absence of isolated failure (progression) within hilar/mediastinal/supraclavicular lymph nodes.

Outcome measures

Outcome measures
Measure	Phase I: Stereotactic Body Radiation (SBRT) n=50 Participants SBRT Dose Level A 9Gy x 5 fractions Dose Level B 10 Gy x 5 fractions Dose Level C 11 Gy x 5 fractions Dose Level D 12 Gy x 5 fractions	Phase I Dose Level B: SBRT 10Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
Phase II Only: Regional Nodal Recurrence Rate	0 percentage of participants	—	—	—

SECONDARY outcome

Timeframe: 2 years

Population: Phase I participants were not evaluable for this outcome measure. 1 patient in Phase II did not come back for follow-up and was excluded from analysis. The remaining 50 participants were analyzed for the outcome measure but only those who were not lost to follow-up or deceased at 2 years were included in the outcome measure results.

Disseminated recurrence is defined as the absence of failure (progression) outside ipsilateral lung and hilar/mediastinal/supraclavicular lymph nodes.

Outcome measures

Outcome measures
Measure	Phase I: Stereotactic Body Radiation (SBRT) n=50 Participants SBRT Dose Level A 9Gy x 5 fractions Dose Level B 10 Gy x 5 fractions Dose Level C 11 Gy x 5 fractions Dose Level D 12 Gy x 5 fractions	Phase I Dose Level B: SBRT 10Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
Phase II Only: Disseminated Recurrence Rate	27 percentage of participants Interval 15.0 to 45.0	—	—	—

SECONDARY outcome

Timeframe: 2 years

Population: Phase I participants were excluded from this outcome measure. 1 patient in Phase II did not come back for follow-up and was excluded from analysis. The remaining 50 participants were analyzed for the outcome measure but only those who were not lost to follow-up or deceased at 2 years were included in the outcome measure results.

Disease-free survival rate is defined as patients without any disease failure (progression), second primary, or death from any cause.

Outcome measures

Outcome measures
Measure	Phase I: Stereotactic Body Radiation (SBRT) n=50 Participants SBRT Dose Level A 9Gy x 5 fractions Dose Level B 10 Gy x 5 fractions Dose Level C 11 Gy x 5 fractions Dose Level D 12 Gy x 5 fractions	Phase I Dose Level B: SBRT 10Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
Phase II Only: Disease-free Survival Rate	28 percentage of participants Interval 16.0 to 42.0	—	—	—

SECONDARY outcome

Timeframe: 2 years

Overall survival is defined as patients alive

Outcome measures

Outcome measures
Measure	Phase I: Stereotactic Body Radiation (SBRT) n=50 Participants SBRT Dose Level A 9Gy x 5 fractions Dose Level B 10 Gy x 5 fractions Dose Level C 11 Gy x 5 fractions Dose Level D 12 Gy x 5 fractions	Phase I Dose Level B: SBRT 10Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
Phase II Only: Overall Survival Rate	43 percentage of participants Interval 28.0 to 57.0	—	—	—

Adverse Events

Phase I Dose Level A: SBRT 9Gy x 5 Fractions

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

Phase I Dose Level B: SBRT 10Gy x 5 Fractions

Serious events: 3 serious events

Other events: 3 other events

Deaths: 1 deaths

Phase I Dose Level C: SBRT 11Gy x 5 Fractions

Serious events: 4 serious events

Other events: 4 other events

Deaths: 2 deaths

Phase I Dose Level D: SBRT 12Gy x 5 Fractions

Serious events: 4 serious events

Other events: 3 other events

Deaths: 3 deaths

Phase II: SBRT 11Gy x 5 Fractions

Serious events: 23 serious events

Other events: 32 other events

Deaths: 35 deaths

Serious adverse events

Serious adverse events
Measure	Phase I Dose Level A: SBRT 9Gy x 5 Fractions n=5 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level B: SBRT 10Gy x 5 Fractions n=6 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions n=6 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions n=6 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase II: SBRT 11Gy x 5 Fractions n=51 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
Investigations Acute - Lymphopenia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Investigations Acute - Neutrophils/granulocytes (ANC/AGC)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Metabolism and nutrition disorders Acute - Glucose, serum-high (hyperglycemia)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Metabolism and nutrition disorders Acute - Sodium, serum-low (hyponatremia)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Musculoskeletal and connective tissue disorders Acute - Arthritis (non-septic)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Eye disorders Acute - Cataract	20.0% 1/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Dyspnea (shortness of breath)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
General disorders Acute - Flu-like syndrome	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Cardiac disorders Late - Atrial fibrillation	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Cardiac disorders Late - Prolonged QTc interval	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Infections and infestations Late - Pneumonia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	21.6% 11/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
General disorders Late - Generalized weakness	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Chest/thorax NOS pain	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Hypoxia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	11.8% 6/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Cough	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	11.8% 6/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Dyspnea	20.0% 1/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	50.0% 3/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	66.7% 4/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	25.5% 13/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Pneumonitis/pulmonary infiltrates	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
General disorders Acute - Fatigue	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Metabolism and nutrition disorders Acute - Anorexia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Metabolism and nutrition disorders Acute - Dehydration	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Infections and infestations Acute - Pneumonia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Infections and infestations Acute - Infection, Other (Urinary tract infection)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Investigations Acute - AST, SGOT	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Investigations Acute - Creatinine	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Metabolism and nutrition disorders Acute - Potassium, serum-low (hypokalemia)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Hypoxia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Pneumonitis/pulmonary infiltrates	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Prolonged intubation thru pulmonary resection (>24 hours thru surgery)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Cardiac disorders Late - Sinus tachycardia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Cardiac disorders Late - Myocardial infarction	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Hemoptysis	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Infections and infestations Late - Port site infection	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Bronchospasm/wheezing	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Obstruction/stenosis of airway	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Pleural effusion	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Pneumothorax	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.

Other adverse events

Other adverse events
Measure	Phase I Dose Level A: SBRT 9Gy x 5 Fractions n=5 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level B: SBRT 10Gy x 5 Fractions n=6 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level C: SBRT 11Gy x 5 Fractions n=6 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase I Dose Level D: SBRT 12Gy x 5 Fractions n=6 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.	Phase II: SBRT 11Gy x 5 Fractions n=51 participants at risk -Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
Blood and lymphatic system disorders Acute - Hemoglobin	20.0% 1/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	7.8% 4/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Investigations Acute - Lymphopenia	20.0% 1/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
General disorders Acute - Fatigue	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Gastrointestinal disorders Acute - Esophagitis	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Metabolism and nutrition disorders Acute - Calcium, serum-low (hypocalcemia)	20.0% 1/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Metabolism and nutrition disorders Acute - Potassium, serum-high (hyperkalemia)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Infections and infestations Late - Pneumonia	20.0% 1/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
General disorders Late - Generalized weakness	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Musculoskeletal and connective tissue disorders Late - Back pain	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Musculoskeletal and connective tissue disorders Late - Chest wall pain	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	7.8% 4/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Chest/thorax NOS pain	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	9.8% 5/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Hypoxia	20.0% 1/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	11.8% 6/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Cough	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	19.6% 10/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Dyspnea (shortness of breath)	20.0% 1/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	13.7% 7/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Obstruction/stenosis of airway	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	16.7% 1/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Pneumonitis/pulmonary infiltrates	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	33.3% 2/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	11.8% 6/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Vascular disorders Acute - Hypertension	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Skin and subcutaneous tissue disorders Acute - Rash: dermatitis associated with radiation	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Gastrointestinal disorders Acute - Dysphagia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Pneumonia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Infections and infestations Acute - Infection, Other (shingles, sepsis)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Metabolism and nutrition disorders Acute - Albumin, serum-low	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Renal and urinary disorders Acute - Proteinuria	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Musculoskeletal and connective tissue disorders Acute - Muscle weakness, generalized or specific area (not due to neuropathy)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Musculoskeletal and connective tissue disorders Acute - Pain - chest wall	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Musculoskeletal and connective tissue disorders Acute - Pain - shoulder	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Acelectasis	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Infections and infestations Acute - Carbon monoxide diffusion capacity	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Cough	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Dyspnea (shortness of breath)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Investigations Acute - FEV(1)	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Acute - Pneumonitis/pulmonary infiltrates	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Cardiac disorders Late - Atrial fibrillation	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Cardiac disorders Late - Sinus tachycardia	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Cardiac disorders Late - Myocardial infarction	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	3.9% 2/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Hemoptysis	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	2.0% 1/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Bronchospasm/wheezing	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.
Respiratory, thoracic and mediastinal disorders Late - Pleural effusion	0.00% 0/5 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	0.00% 0/6 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.	5.9% 3/51 • Acute adverse events from protocol radiation therapy was collected from start of treatment until 90 days. Late adverse events from protocol radiation therapy was collected from day 91 until completion of follow-up. Mean follow-up for Dose Level A=22.9 months (full range 6-47), Dose Level B=25.3 months (full range 2-42), Dose Level C=17.3 months (full range 13-22), Dose Level D 6.6 months (full range 1-11), Phase II=17 months (full range 2-57). Grade 2 or above acute and late adverse events from protocol radiation therapy were collected. For purposes of this protocol, serious adverse events related to stereotactic radiation therapy include those listed as Grade 3-5 within the CTCAE document. All-cause mortality was followed from start of treatment until completion of follow-up or death, whichever came first.

Additional Information

Clifford Robinson, M.D.

Washington University School of Medicine

Phone: 314-362-4633

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place